Lv1
60 积分 2025-05-16 加入
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
28天前
已完结
Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective
3个月前
已完结
Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-Resistant Prostate Cancer
3个月前
已完结
CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling
3个月前
已完结
Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide
5个月前
已完结
A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together
5个月前
已完结
Cross‐Linking Profiling of Molecular Glue Degrader‐Induced E3 Ligase Interactome to Expand Target Space
5个月前
已完结
A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy
9个月前
已完结
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
9个月前
已完结
A High-Affinity Antibody-Drug Conjugates Actuximab-MMAE for Potent and Selective Targeting of CEACAM5-Positive Tumors
11个月前
已完结
皖公网安备34019202002308
